Netherlands Compounding Pharmacies Market | Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• NETHERLANDS COMPOUNDING PHARMACIES MARKET
  ANALYSIS
• Netherlands Compounding Pharmacies Market, By
  Product Type (Mouthwashes, Oral Medication
  (Capsule, Lollipops, Lozenges, Suspensions,Tablets
  ), Suppositories Topical Medication (Cream, Gels,
  Lotions, Ointments)), By Application (Medication
  for Adults, Medication for Children, Medication
  for Geriatric, Medication for Veterinary), By
  Therapeutic Area (Hormone Replacement Therapy,
  Pain Management), By Facilities (Community
  Pharmacies, Hospitals) - Size, Share, Outlook,
  and Opportunity Analysis, 2019 - 2027

3

• Netherlands Compounding Pharmacies Market
  Drivers
• Increasing prevalence of chronic diseases is
  expected to boost growth of the Netherlands
  compounding pharmacies market over the forecast
  period. For instance, according to Globocan 2018,
  119,923 cases of cancer were registered in the
  Netherlands.
• Moreover, decreasing supply of essential drugs is
  also expected to propel growth of the market. For
  instance, according to Royal Dutch Society for
  the Promotion of Pharmacy (KNMP), 769 medicines
  were unavailable at some stage during 2018,
  including 128 treatments that were taken out of
  circulation altogether.
• Oral medication held dominant position in the
  Netherlands compounding pharmacies market in
  2018, accounting for 62.9 share in terms of
  value, followed by topical medication.

4

5

• Netherlands Compounding Pharmacies Market
  Restraints
• However, a major factor hindering growth of the
  Netherlands compounding pharmacies market is
  adoption of unsafe compounding practices such as
  compounding contamination and non-adherence to
  GMP regulations.
• Moreover, certain compounded drugs in the
  Netherlands have been associated with adverse
  drug reactions as they constitute drugs that are
  banned under pharmacovigilance measures. Adverse
  drug reactions prove detrimental to patients and
  related partys confidence in compounded drugs.
  For instance, clioquinola drug used for
  controlling amoebiasis and infections with
  dientamoeba fragilisis no longer registered
  through the Medicines Evaluation Board for
  systemic use in the Netherlands and is only
  available as a compounded drug. In 2015,
  according to Netherlands Pharmacovigilance
  Center, use of clioquinol in compounded form led
  to 33 reports concerning adverse drug reactions.

6
Netherlands Compounding Pharmacies Market
Opportunities

• Increasing GMP compliance is expected to offer
  lucrative growth opportunities for players in the
  Netherlands compounding pharmacies market.
  Currently, inspection for adherence to GMP
  guidelines is only available for industrial
  manufacturing of drugs in the Netherlands.
  However, community compounding pharmacies need to
  adhere to best practice guidelines, as hospitals
  in the country are expected to outsource more
  drug compounding to the community compounding
  pharmacies.
• Key players in the market can also focus on RD
  of products related to geriatric and long-term
  care and innovative Hormone replacement therapy
  (HRT) applications to expand their product
  portfolio.

7
Market Trends/Key Takeaways

• The market is witnessing increasing preference
  for HRT drugs for indications such as menopausal
  symptoms, mens health (andropause), and weight
  loss. However, untested ingredients, possibility
  of microbiological contaminations, errors in
  defining dosages of hormones and declining
  reimbursements from government are some of the
  factors that may hamper demand for HRT drugs in
  the Netherlands.
• In the Netherlands, products are primarily
  purchased from specialized compounding companies
  and products from major market players are in
  high demand compared to those of community
  compounding pharmacies. Moreover, a majority of
  compounded drugs are outsourced to hospitals.

8
Netherlands Compounding Pharmacies Market Key
Developments

• Key players in the market are focused on
  geographical expansion through MA activities.
  For instance, in May 2019, Fagron entered into an
  agreement to acquire Central de Drogas, S.A. de
  C.V., a leading supplier of raw materials to
  compounding pharmacies and the pharmaceutical
  industry in Mexico.
• Key players in the market are also focused on
  product development to expand their product
  portfolio. For instance, in November 2018, AMC, a
  hospital in Amsterdam focused on producing
  compounding drugs, received permission from the
  Dutch Health and Youth Care Inspectorate to
  produce an equivalent of chenodeoxycholic acid
  (CDCA) if the used resources meet the quality
  standards.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/netherlands-compounding-pharmacies-
  market-3156

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/